Wczytywanie kursów wyceny...
Prognoza
Nie mamy danych analityków dla tej spółki.
Wiadomości Przejdź do aktualności
First Tracks Biotherapeutics expects key ANB033 study data and has funding through Q2 2028
First Tracks Biotherapeutics presented its pipeline at the Wells Fargo Healthcare Conference, focusing on ANB033, a CD122 antibody that blocks both IL-15 and IL-2 signaling pathways and is in a Phase I–II study for celiac disease and eosinophilic esophagitis (EoE). The company cited near-term data milestones: cohort 1 (gluten challenge) in Q4 2024, cohort 2 (healing) in Q1 2025, and EoE data in H2 2025. First Tracks highlighted ANB033’s differentiating dual mechanism and subcutaneous dosing, viewing it as a potential first program to address both TH2 and CD8 pathways. Management said existing cash is expected to fund operations through Q2 2028 and plans, depending on the data, to expand into additional indications in H1 2027. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | czerwiec 2026 | |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | -181,38 tys. | - |
| Zysk netto | -29,24 mln | - |
| EBITDA | -30,43 mln | - |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 1,17 mld € |
Liczba akcji | 34,89 mln |
Maksimum/minimum z 52 tygodni | 43,49 € - 12,83 € |
| Dywidendy | Nie |
Beta | 3,37 |
C/Z (PE Ratio) | -16,10 |
PEG (PEG Ratio) | -0,16 |
C/WK (PB Ratio) | 8,07 |
C/S (PS Ratio) | 0,00 |
Profil spółki
| Nazwa | FIRST TRACKS BIOTHERAP. |
| CEO | Daniel R. Faga |
| Pracownicy | 104 |
